
Bevacizumab Biosimilar Granted FDA Approval for Several Cancer Types
The FDA granted approval to bevacizumab-nwgd (Jobevne), a biosimilar for bevacizumab (Avastin), for indications in several cancer types including colorectal cancer; non-squamous non-small cell lung cancer; glioblastoma; renal cell carcinoma; cervical …